Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Davenport-Moline-Rock Island, IA-IL MSA — September 2026
Quad Cities jobs shrink even as unemployment falls.
Davenport-Moline-Rock Island lost 2,100 nonfarm jobs year-over-year even as unemployment dropped to 4.2%, while local Research Scientist pay ($155,478) climbed well above the national median ($131,354).
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Metro unemployment rate: 4.2% — August 2026, down from 4.0% in July
- Metro nonfarm employment change: -2,100 jobs — Year-over-year, largest % decline in Illinois metros
- Illinois labor force change: -94,600 workers — Year-over-year through August 2026
- U.S. unemployment rate: 4.1% — One-year low, unchanged since July 2026
Key takeaways
Falling jobs, falling unemployment — a mismatched signal.
Local nonfarm employment declined 2,100 positions year-over-year while unemployment dropped to 4.2%, consistent with workers exiting the labor force rather than genuine hiring strength. Life Sci leaders should treat the low local jobless rate skeptically when forecasting candidate pipeline depth.
Research Scientist pay outpaces national trend sharply.
Metro median advertised pay for Research Scientist roles sits at $155,478, well above the $131,354 national figure, both trending up significantly. That local premium may reflect genuine scarcity rather than cost-of-living adjustment — worth testing against actual fill rates before assuming it's sustainable.
Regulatory Affairs pay diverges from its national ceiling.
Metro Regulatory Affairs Specialist pay is advertised at $93,330 versus a stable national median of $104,000, a gap that could make local hiring more cost-efficient — but also signals the metro may struggle to attract senior regulatory talent commanding national premiums reported elsewhere this month ($320K–$580K for VP-level roles).
CRA pay rising locally and nationally, unevenly.
Clinical Research Associate advertised pay climbed significantly both in the metro ($83,763) and nationally ($90,956), with the metro still trailing by roughly $7,200. Sustained national pull may draw clinical operations talent toward larger biopharma hubs, pressuring Quad Cities employers to close the gap or lean further on CRO partnerships.
Median advertised pay by role — Davenport-Moline-Rock Island, IA-IL MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $96,319 | $155,478 | $180,500 | Significant increase | $131,354 |
| Clinical Research Associate * | $63,752 | $83,763 | $100,011 | Significant increase | $90,956 |
| Lab Technician * | $40,473 | $46,621 | $52,991 | Stable | $47,402 |
| Regulatory Affairs Specialist * | $68,679 | $93,330 | $114,685 | Significant increase | $104,000 |
| Clinical Data Manager * | $97,834 | $121,911 | $121,911 | Stable | $123,031 |
| Biostatistician * | $94,961 | $130,897 | $152,459 | Stable | $133,322 |
| Validation Engineer * | $85,000 | $99,647 | $106,081 | Stable | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Davenport-Moline-Rock Island's unemployment rate fell to 4.2% in August even as total nonfarm employment dropped 2,100 jobs year-over-year — a divergence suggesting labor force contraction, not hiring strength, is pulling the rate down. Illinois' statewide labor force shrank by 94,600 workers over the same period, compounding scarcity for credential-heavy scientific and regulatory roles that already face long ramp times and thin regional bench strength.
What it means
A shrinking labor force against falling local employment means Life Sci leaders in the Quad Cities can't count on rate-driven easing to widen the regulatory, quality, or CMC candidate pool — the math points to continued scarcity for specialized credentials even as headline unemployment looks benign. Build-vs-outsource tradeoffs tilt further toward CDMO and CRO partnerships for execution-critical but hard-to-staff functions, particularly where national premiums for regulatory affairs and process chemistry talent make in-house hiring slower and costlier. Consider reviewing which R&D, quality, and manufacturing roles face the longest open-requisition timelines locally, and model outsourcing cost against the real carrying cost of unfilled specialized seats.
Looking ahead
Worth watching: September's official BLS metro release (due October 28) will clarify whether the employment decline accelerates or stabilizes — a key input for headcount planning across R&D, clinical, and manufacturing functions.
Emerging pressure point: Illinois WARN filings reached 91 notices and 16,782 affected workers year-to-date, concentrated outside life sciences so far. Watch whether displaced talent from sectors like information or financial activities begins entering adjacent scientific or quality roles.
Potential inflection point: National biopharma layoffs (BioMarin, Bristol Myers) are concentrated in consolidation functions while 64% of surveyed organizations keep recruiting. Quad Cities employers should monitor whether any released specialized talent — particularly regulatory or CMC — becomes available regionally.
Early indicator: GLP-1 pipeline expansion is intensifying national competition for manufacturing, quality, and regulatory talent. Track whether this pressure reaches regional CDMO capacity or advertised pay for Validation Engineer and CMC-adjacent roles locally.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.